Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 7, 2026, 3:02 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 416 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: insulin infusion Clear all
Terminated Not applicable Interventional Results available

Glycemic Control to Prevent Cardiac Morbidity in Vascular Surgery

NCT00328094
View directory record Official record
Conditions
Peripheral Vascular Disease, Abdominal Aortic Aneurysm
Interventions
continuous intravenous insulin infusion
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 16, 2013 · Synced Sep 7, 2026, 3:02 PM EDT
Not listed Not applicable Interventional

Inpatient Self Monitoring and Administration Study (ISMAS)

NCT00506272
View directory record Official record
Conditions
Diabetes Mellitus, Hyperglycemia, Hypoglycemia
Interventions
Self blood glucose monitoring and insulin administration, Standard care
Procedure
Lead sponsor
Atlanta VA Medical Center
Federal
Eligibility
18 Years to 80 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
1
States / cities
Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 13, 2015 · Synced Sep 7, 2026, 3:02 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Metabolic Causes of Thrombosis in Type 2 Diabetes Mellitus

NCT00829699
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
euinsulinemic euglycemic glucose clamp, euinsulinemic hyperglycemic glucose clamp, Hyperinsulinemic euglycemic glucose clamp, Hyperinsulinemic hyperglycemic glucose clamp
Procedure
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 60 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 11, 2019 · Synced Sep 7, 2026, 3:02 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Alpelisib Challenge Test (ACT)

NCT07778524
View directory record Official record
Conditions
Insulin Resistance, Type 2 Diabetes, Obesity & Overweight, Healthy Adult Participants
Interventions
Alpelisib 300 mg, Alpelisib Challenge Test (ACT): Mixed Meal Tolerance Test (MMTT) after taking alpelisib, Hyperglycemic clamp
Drug · Diagnostic Test
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 70 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Sep 7, 2026, 3:02 PM EDT
Recruiting Not applicable Interventional

Effect of Physiologic Insulin Administration on Insulin Sensitivity and Cognition

NCT07265323
View directory record Official record
Conditions
Alzheimer s Disease, Alzheimer Blood Biomarkers, Insulin Sensitivity
Interventions
Physiological Insulin Intervention
Other
Lead sponsor
Pennington Biomedical Research Center
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Dec 3, 2025 · Synced Sep 7, 2026, 3:02 PM EDT
Completed Phase 1 Interventional Results available

A Study of IMC-A12 in Participants With Tumors Who No Longer Respond to Treatment or For Whom No Treatment is Available

NCT00785538
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
IMC-A12
Biological
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
3
States / cities
Scottsdale, Arizona • Detroit, Michigan • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 7, 2019 · Synced Sep 7, 2026, 3:02 PM EDT
Completed Not applicable Interventional Results available

Glutathione Metabolism in Adolescents With Type 1 Diabetes - Study A

NCT00858897
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Cysteine isotope infusion at normoglycemia vs hyperglycemia, Regular Insulin
Other · Drug
Lead sponsor
Nemours Children's Clinic
Other
Eligibility
14 Years to 18 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jul 9, 2023 · Synced Sep 7, 2026, 3:02 PM EDT
Completed Not applicable Interventional Results available

Two Way Crossover Closed Loop Study R-AP vs MPC

NCT05083559
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
MPC AP algorithm, Robust R-AP algorithm
Device
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jan 19, 2023 · Synced Sep 7, 2026, 3:02 PM EDT
Completed Not applicable Interventional

Comparison of Intraoperative Best Practice Advisory Reminders to Protocolize Insulin Administration Versus Standard Care in Patients at High Risk of Hyperglycemia

NCT05426096
View directory record Official record
Conditions
Diabetes, Hyperglycemia
Interventions
Best Practice Advisory
Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
Not listed
Enrollment
7,232 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 7, 2024 · Synced Sep 7, 2026, 3:02 PM EDT
Withdrawn Phase 1 Interventional

Dexamethasone/Pancreatic Clamp P&F

NCT06126354
View directory record Official record
Conditions
Insulin Resistance, Prediabetic State, Non-Alcoholic Fatty Liver Disease, Overweight and Obesity
Interventions
Insulin human, Octreotide Acetate, Glucagon, Human Growth Hormone, Dexamethasone Oral, [6,6-2H2] D-glucose, 20% D-glucose (aq), BOOST Plus, Harvard Apparatus PHD ULTRA CP syringe pump, Yellow Springs Instruments (YSI) 2500 Biochemistry Glucose/Lactate Analyzer, Normal saline, Human albumin
Drug · Other · Dietary Supplement + 1 more
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 9, 2024 · Synced Sep 7, 2026, 3:02 PM EDT
Completed Not applicable Interventional

A Study of an Automated Insulin Delivery System in Adult Participants With Type 1 Diabetes Mellitus

NCT03849612
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
AID System, Insulin Lispro
Device · Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Walnut Creek, California
Source: ClinicalTrials.gov public record
Updated Apr 24, 2019 · Synced Sep 7, 2026, 3:02 PM EDT
Withdrawn Phase 1Phase 2 Interventional

Effectiveness Study of Pramlintide to Treat Post-Transplant Diabetes Mellitus

NCT01165944
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Pramlintide
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
20 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jul 25, 2018 · Synced Sep 7, 2026, 3:02 PM EDT
Completed Not applicable Interventional Results available

Automated Insulin Delivery for INpatients With DysGlycemia (AIDING) Feasibility

NCT04714216
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
The Omnipod 5/Horizon HCL system
Device
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
3
States / cities
Stanford, California • Atlanta, Georgia • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 22, 2024 · Synced Sep 7, 2026, 3:02 PM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Comparing Soybean Oil-Based (Intralipid) With an Olive Oil-Based (ClinOleic) Lipid Emulsion on Healthy Volunteers

NCT02185729
View directory record Official record
Conditions
Diseases, Metabolic, Insulin Sensitivity
Interventions
Intralipid, ClinOleic, Dextrose, Saline (control)
Drug · Other
Lead sponsor
Emory University
Other
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2012
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 30, 2014 · Synced Sep 7, 2026, 3:02 PM EDT
Completed Phase 1 Interventional

GIP: Glucose-dependent Insulinotropic Peptide

NCT00239707
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
GIP, Modified GIP, Normal Saline
Drug
Lead sponsor
National Institute on Aging (NIA)
NIH
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 27, 2013 · Synced Sep 7, 2026, 3:02 PM EDT
Completed Phase 2 Interventional Results available

Study of AMG 479 as Second Line Therapy in Patients With Recurrent Platinum-sensitive Ovarian Cancer

NCT00719212
View directory record Official record
Conditions
Ovarian Neoplasms
Interventions
AMG 479
Biological
Lead sponsor
Translational Research in Oncology
Other
Eligibility
18 Years and older · Female only
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
16
States / cities
Bakersfield, California • Fullerton, California • La Verne, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2016 · Synced Sep 7, 2026, 3:02 PM EDT
Completed Phase 4 Interventional Results available

Adding Exenatide to Insulin Therapy for Patients With Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease

NCT01006889
View directory record Official record
Conditions
Nonalcoholic Fatty Liver Disease, Type 2 Diabetes Mellitus
Interventions
Exenatide
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 27, 2016 · Synced Sep 7, 2026, 3:02 PM EDT
Completed No phase listed Observational

Insulin Infusion in the Hospital Wards

NCT00412347
View directory record Official record
Conditions
Hyperglycemia
Interventions
Insulin Drip Therapy
Drug
Lead sponsor
Emory University
Other
Eligibility
19 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 10, 2014 · Synced Sep 7, 2026, 3:02 PM EDT
Withdrawn Not applicable Interventional

Use of the Insulin Pump in Cystic Fibrosis Patients With Impaired Glucose Tolerance or CFRD and in Type 1 Diabetes Patients.

NCT00287456
View directory record Official record
Conditions
Cystic Fibrosis Related Diabetes
Interventions
Insulin Pump, Insulin, Oral Glucose Tolerance Test, Whole body Protein Turnover
Device · Drug · Procedure
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
12 Years to 32 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 9, 2019 · Synced Sep 7, 2026, 3:02 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Understanding the Relationship Between Inflammation and Insulin Resistance in the Adipose Tissue

NCT02378077
View directory record Official record
Conditions
Obesity, Insulin Resistance
Interventions
Fat biopsy during scheduled abdominal surgery, Fat Aspiration, Fish Oil Supplement
Procedure · Dietary Supplement
Lead sponsor
Mayo Clinic
Other
Eligibility
30 Years to 50 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Jan 17, 2020 · Synced Sep 7, 2026, 3:02 PM EDT
Withdrawn Phase 3 Interventional

Intensive Glycemic Control on Infectious Morbidity In Patients With Acute Leukemia

NCT00943709
View directory record Official record
Conditions
Hyperglycemia, Leukemia
Interventions
insulin glargine recombinant, therapeutic insulin
Biological · Drug
Lead sponsor
University of Medicine and Dentistry of New Jersey
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 29, 2013 · Synced Sep 7, 2026, 3:02 PM EDT
Completed Phase 1 Interventional

Pancreatic Clamp in NAFLD

NCT05724134
View directory record Official record
Conditions
Insulin Resistance, Prediabetic State, Hyperinsulinemia, Non-Alcoholic Fatty Liver Disease, Obesity
Interventions
Insulin human, Octreotide Acetate, Glucagon, Growth Hormone, Human, [6,6-2H2] D-glucose, 20% D-glucose (aq), BOOST Plus, CORE Bar, Harvard Apparatus PHD ULTRA CP syringe pump, Yellow Springs Instruments (YSI) 2500 Biochemistry Glucose/Lactate Analyzer
Drug · Other · Dietary Supplement + 1 more
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 11, 2026 · Synced Sep 7, 2026, 3:02 PM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

Effects of Xenin-25 on Insulin Secretion and Gastric Emptying in Humans With and Without a Complete Truncal Vagotomy

NCT01951716
View directory record Official record
Conditions
Does the Vagus Nerve Mediate the Effects of Xenin-25
Interventions
Graded Glucose Infusion with Placebo, Graded Glucose Infusion with GIP Alone, Graded Glucose Infusion with xenin-25 alone, Graded Glucose Infusion with GIP plus xenin-25, Meal Tolerance Test with Placebo, Meal Tolerance Test with xenin-25
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2018
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 25, 2018 · Synced Sep 7, 2026, 3:02 PM EDT
Completed Phase 2 Interventional Results available

Artificial Pancreas Control System in an Inpatient Setting

NCT01552603
View directory record Official record
Conditions
Type I Diabetes Mellitus
Interventions
Artificial Pancreas Control Software
Device
Lead sponsor
Legacy Health System
Other
Eligibility
21 Years to 65 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
2
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jun 2, 2016 · Synced Sep 7, 2026, 3:02 PM EDT